Navigation Links
11th International Congress on Targeted Anticancer Therapies
Date:2/28/2013

Lugano/Amsterdam, 28 February 2013 -- A range of new and promising targeted drugs currently under development for improved cancer therapy will be presented during the 11th International Congress on Targeted Anticancer Therapies, Paris, 4-6 March 2013 (TAT 2013). The event, which is organised by NDDO Education Foundation, is an ESMO Partnership Meeting, co-sponsored by the U.S. National Cancer Institute.

Over 500 oncologists and scientists from all over the world will review and discuss cancer therapies of the future. Among them, many top academic experts involved in the early-phase clinical development of new targeted therapeutics and molecular cancer diagnostics, the cornerstones of personalised cancer therapy .

Personalised cancer medicine: targets and therapeutics

The development of new targeted cancer therapies is one of the main drivers for the further evolution of personalized cancer medicine. The concept of personalized medicine is based upon the notion that cancer development and progression are driven by genomic abnormalities and that these abnormalities are different not only between different types of cancer, but also between individual patients. Such findings have opened the door to the development of targeted cancer therapeutics, directed against tumour-specific molecular abnormalities.

At TAT 2013, over 50 plenary lectures and 70 posters will address dozens of emerging targeted agents and new drug targets under development for cancer therapy. In particular targets and experimental therapeutics in the early stages of clinical and the late stages of preclinical development will be addressed.

Program Highlights

  • Keynote Lecture "Targeting immune checkpoints in cancer therapy" (Michael B. Atkins, Washington, DC);
  • "New immune checkpoints as targets", featuring updates on four promising global drug development programmes targeting the immune system in cancer patients;
  • "Metabolic drug targets", featuring updates on three major drug development programmes trying to exploit abnormalities in tumour cell metabolism;
  • "Phase 1 studies, completed or in progress", featuring seven targeted drugs in phase 1, including brand-new data;
  • "Whole-genome sequencing in early-phase drug development", addressing issues around the implementation of genomics already in the early clinical phases of drug development in order to better identify patients that will benefit from the new drug;
  • NDDO Honorary Award Lecture 2013 "Phase 1, a critical step for cancer drug development" (Jean-Pierre Armand, Paris, France)


'/>"/>
Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. Ultracold matter technology from CU and SRI International licensed to Boulders ColdQuanta
2. International Polar Year conference: From knowledge to action
3. Large international study finds memory in adults impacted by versions of 4 genes
4. International team uncovers new genes that shape brain size, intelligence
5. Southampton researchers lead 2 international projects to help people out of poverty
6. UCSD researchers: Where international climate policy has failed, grassroots efforts can succeed
7. Washington University receives $8 million to lead international childhood malnutrition effort
8. Early Bird Discounts Available on International Healthcare and Biotechnology Conferences, Save Up To $600 with Global Information
9. New HealthFocus® International Study Reveals Five Very Different Weight Management Consumers
10. OU scientists and international team deciper the genetic code of the tomato
11. Digicel Launches Worlds First Biometric Identification System For International Money Transfers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
Breaking Biology News(10 mins):
(Date:9/19/2017)... ... September 19, 2017 , ... ... Services (NYS DFS) cybersecurity regulations have transitioned into full force and ... operating in the state (“Covered Entities”) to conduct an annual, professional, comprehensive ...
(Date:9/18/2017)... ... September 18, 2017 , ... ... the move of the SPIE Digital Library ( http://www.spiedigitallibrary.org ) on 15 August ... create an improved user experience and incorporate a number of enhancements and new ...
(Date:9/17/2017)... ... , ... GeneOne Life Science, Inc. announces that it has ... for an Investigational New Drug application for a Phase I/IIa study of its ... in Korea represents the second clinical trial for GLS-5300. , A US ...
(Date:9/14/2017)... Philadelphia PA and London UK (PRWEB) , ... ... ... company, will gather the most innovative minds in pharma and biotech at the ... is a two-day collaborative conference that brings together the world’s most progressive clinical ...
Breaking Biology Technology: